Trial Profile

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Infliximab (Primary) ; Mycophenolate mofetil (Primary)
Indications Carcinoma; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms MERMAID-2
Sponsors AstraZeneca; AstraZeneca AB

15 Mar 2024 This trial has been completed in Denmark (Global end date: 15 Jan 2024).
14 Mar 2024 Status changed from active, no longer recruiting to completed.
08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com